FLT3 inhibitors, midostaurin and gilteritinib, were demonstrated to strongly enhance the antileukemic activity of venetoclax in FLT3-mutated AML cell lines, primary patient samples, and mouse xenograft models, at least partially through downregulation of Mcl-1.124. Here, FLT3 is linked to acute myeloid leukemia.